Dexamethasone Neomycin Polymyxin B Phenylephrine –

Description

Latin name

Polydexa with phenylephrine

release form

Nasal spray

Packaging

15 ml in a bottle complete with a spray, in a cardboard box.

¤ °Ñ ¼ ° º ¾ » ¾ ³ ¸Ñ‡ с º ¾ ´ ¹ÑÑ ² ¸

š ¾ ¼ ± ¸ ½ ¸Ñ ¾ ² ° ½ ½ ¹ ¿Ñ ¿ °Ñ °Ñ ´ »Ñ ¼ ÑÑ ½ ¾ ³ ¾ ¿Ñ ¸ ¼ ½ ½ ¸Ñ ² ¾Ñ ¾Ñ ¸ ½ ¾ » °Ñ ¸ ½ ³ ¾ » ¾ ³ ¸ ¸.

¢ Ñ ° ¿ ²Ñ ¸Ñ‡ с º ¸ ¹ эфф ºÑ ¿Ñ ¿ °Ñ °Ñ ° Ÿ ¾ » ¸ ´ ºÑ ° с ф ½ ¸ »ÑÑ„Ñ ¸ ½ ¾ ¼ ¾ ±ÑƒÑ » ¾ ² » ½ ¿Ñ ¾Ñ ¸ ² ¾ ² ¾Ñ ¿ ° » ¸Ñ »ÑŒ ½ ¼ ´ ¹ÑÑ ² ¸ ¼ ´ ºÑ ° ¼ Ñ ° · ¾ ½ ° ½ ° с » ¸ · ¸ÑÑ ую ¾ ± ¾ » ¾Ñ‡ ºÑƒ ½ ¾Ñ °, с ¾ÑÑƒ ´ ¾ÑÑƒ ¶ ¸ ² °ÑŽÑ‰ ¸ ¼ ´ ¹ÑÑ ² ¸ ¼ ф ½ ¸ »ÑÑ„Ñ ¸ ½ ° ¸ ° ½Ñ ¸ ± ° ºÑ Ñ ¸ ° »ÑŒ ½ ¼ ´ ¹ÑÑ ² ¸ ¼ ° ½Ñ ¸ ± ¸ ¾Ñ ¸ º ¾ ² ½ ¾ ¼ ¸Ñ† ¸ ½ ° ¸ ¿ ¾ » ¸ ¼ ¸ ºÑ ¸ ½ ° B.

ŸÑ ¸ с ¾Ñ‡ Ñ ° ½ ¸ ¸ у º ° · ° ½ ½ х ° ½Ñ ¸ ± ¸ ¾Ñ ¸ º ¾ ² Ñ °ÑÑˆ ¸Ñ я Ñ ÑÑ с ¿ ºÑ Ñ ° ½Ñ ¸ ± ° ºÑ Ñ ¸ ° »ÑŒ ½ ¾ ³ ¾ ´ ¹ÑÑ ² ¸Ñ ½ ° ± ¾ »ÑŒÑˆ ¸ ½ÑÑ ² ¾ ³Ñ ° ¼ ¿ ¾ » ¾ ¶ ¸Ñ »ÑŒ ½ х ¸ ³Ñ ° ¼ ¾Ñ Ñ ¸Ñ† °Ñ »ÑŒ ½ х ¼ ¸ ºÑ ¾ ¾Ñ ³ ° ½ ¸ · ¼ ¾ ², ² · ² °ÑŽÑ‰ ¸Ñ… ¸ ½Ñ„ ºÑ† ¸ ¾ ½ ½ ¾- ² ¾Ñ ¿ ° » ¸Ñ »ÑŒ ½ · ° ± ¾ » ² ° ½ ¸Ñ ½ ¾Ñ ¾ ² ¾ ¹ ¿ ¾ » ¾ÑÑ ¸ ¸ ¿Ñ ¸ ´ °Ñ ¾Ñ‡ ½ х ¿ ° ·ÑƒÑ….

Indications

Infectious and inflammatory diseases of the nasal cavity, pharynx, sinuses:

acute and chronic rhinopharyngitis

acute and chronic rhinitis

sinusitis.

Contraindications

simultaneous use of monoamine oxidase inhibitors

suspected angle-closure glaucoma

viral diseases

kidney disease, albuminuria accompanied

pregnancy

breastfeeding

child age (up to 2, 5 years)

hypersensitivity to the components of the drug.

Pregnancy and lactation

Polydex with phenylephrine is contraindicated during pregnancy and lactation (breastfeeding).

Composition of

15 ml spray contains:

Active ingredients:

neomycin sulfate 1 g, which corresponds to 650,000 ME

polymyxin B sulfate 1,000,000 ME

dexamethasone sodium metasulfobenzoate 0.225 g srdlprplo phenyl lithium chloride,

citric acid,

lithium hydroxide,

macrogol 400,

polysorbate 80,

purified water qs up to 100 ml

Dosage and administration of

Adults: one injection into each nostril 3-5 times a day.

For children aged 2.5 to 15 years: one injection into each nostril 3 times a day.

Duration of treatment is 5-10 days.

Side effects

Allergic reactions: rarely – skin manifestations.

Drug Interaction

The drug interaction is due to the phenylephrine content.

The concomitant use of guanethidine and drugs in this group increases the hypertensive effect of phenylephrine and, by reducing the sympathetic tone with guanethidine, prolonged mydriasis is possible.

If such a combination cannot be avoided, then a doctor’s observation is required.

Overdose

Due to the low degree of absorption into the systemic circulation, an overdose is unlikely.

Storage conditions

At a temperature not exceeding 25 ° C, out of the reach of children.

Shelf suitability

3 Year

dosage form

dosage form

nasal spray

Laboratory Bouchard, France